Enfusion, Inc. (ENFN)
Total Valuation
Enfusion has a market cap or net worth of $811.28 million. The enterprise value is $747.73 million.
Market Cap | 811.28M |
Enterprise Value | 747.73M |
Important Dates
The next earnings date is Thursday, March 23, 2023, after market close.
Estimated Earnings Date | Mar 23, 2023 |
Ex-Dividend Date | n/a |
Share Statistics
Enfusion has 68.99 million shares outstanding. The number of shares has decreased by -24.68% in one year.
Shares Outstanding | 68.99M |
Shares Change (YoY) | -24.68% |
Shares Change (QoQ) | +55.78% |
Owned by Insiders (%) | 4.65% |
Owned by Institutions (%) | 108.00% |
Float | n/a |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 67.11 |
PS Ratio | 5.73 |
Forward PS | 4.19 |
PB Ratio | 13.27 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 5.28 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.01
Current Ratio | 8.01 |
Quick Ratio | 7.72 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Financial Efficiency
Return on equity (ROE) is -309.20% and return on invested capital (ROIC) is -447.60%.
Return on Equity (ROE) | -309.20% |
Return on Assets (ROA) | -163.10% |
Return on Capital (ROIC) | -447.60% |
Revenue Per Employee | $158,840 |
Profits Per Employee | -$199,683 |
Employee Count | 892 |
Asset Turnover | 1.30 |
Inventory Turnover | n/a |
Taxes
In the past 12 months, Enfusion has paid $531,000 in taxes.
Income Tax | 531,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -2.89% in the last 52 weeks.
Beta (1Y) | n/a |
52-Week Price Change | -2.89% |
50-Day Moving Average | 10.70 |
200-Day Moving Average | 11.49 |
Average Volume (30 Days) | 320,354 |
Short Selling Information
The latest short interest is 1.86 million, so 2.70% of the outstanding shares have been sold short.
Short Interest | 1.86M |
Short Previous Month | 1.66M |
Short % of Shares Out | 2.70% |
Short % of Float | n/a |
Short Ratio (days to cover) | 5.70 |
Income Statement
In the last 12 months, Enfusion had revenue of $141.69 million and -$178.12 million in losses. Loss per share was -$3.05.
Revenue | 141.69M |
Gross Profit | 97.72M |
Operating Income | -305.83M |
Pretax Income | -177.59M |
Net Income | -178.12M |
EBITDA | -171.30M |
EBIT | -177.27M |
Loss Per Share | -$3.05 |
Balance Sheet
Cash & Cash Equivalents | 63.54M |
Total Debt | n/a |
Net Cash | 63.54M |
Net Cash Per Share | $0.92 |
Equity / Book Value | 61.13M |
Book Value Per Share | 0.89 |
Working Capital | 84.04M |
Cash Flow
In the last 12 months, operating cash flow was $823,000 and capital expenditures -$7.83 million, giving a free cash flow of -$7.00 million.
Operating Cash Flow | 823,000 |
Capital Expenditures | -7.83M |
Free Cash Flow | -7.00M |
FCF Per Share | -$0.08 |
Margins
Gross margin is 68.97%, with operating and profit margins of -215.85% and -125.71%.
Gross Margin | 68.97% |
Operating Margin | -215.85% |
Pretax Margin | -125.34% |
Profit Margin | -125.71% |
EBITDA Margin | -120.90% |
EBIT Margin | -125.11% |
FCF Margin | -4.94% |
Dividends & Yields
Enfusion does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Earnings Yield | -21.96% |
FCF Yield | -0.86% |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Buyback Yield | 24.68% |
Shareholder Yield | 24.68% |
Analyst Forecast
The average price target for Enfusion is $13.06, which is 11.05% higher than the current price. The consensus rating is "Buy".
Price Target | $13.06 |
Price Target Difference | 11.05% |
Analyst Consensus | Buy |
Analyst Count | 12 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |